Lasa Supergenerics Ltd.
4.91
INR
-0.25
(-4.84%)
ISIN
INE670X01014
Return %
Stock
S&P 500
1Y
-52.97
14.20
3Y
-81.71
81.12
5Y
-92.38
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Omkar Pravin Herlekar
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Plot no. C-4 Ratnagiri MA India 415722
- IPO Date
- Sep 21, 2017
- Website
- lasalabs.com
- Similar Companies
- Business
- Lasa Supergenerics Limited is a vertically integrated pharmaceutical company specializing in the research, manufacturing, and global marketing of active pharmaceutical ingredients (APIs) and allied products primarily for the animal and human healthcare sectors. The company’s core product portfolio includes anthelmintic and veterinary APIs such as Albendazole, Fenbendazole, Oxfendazole, Ricobendazole, Halquinol, Providone Iodine, Nitroxylene, and other specialized catalyst chemistry products. Additionally, it produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Lasa operates manufacturing facilities located in Mahad and Chiplun in Maharashtra, India, featuring extensive capabilities in backward integration from molecule discovery through full-scale bulk production. Founded in 1997 and headquartered in Mumbai, India, Lasa Supergenerics serves a diverse global customer base with a strong focus on developing markets. The company is positioned within the pharmaceutical API and veterinary medicine industry, leveraging its expertise in catalyst chemistry to maintain a competitive edge in both product innovation and manufacturing scale. Recent operational developments include recovery and resumption of manufacturing activities after a fire incident in 2025 and strategic ongoing expansion plans for its mother manufacturing unit in Lote Parshuram Industrial Area to consolidate production and backward integration processes under one unit. In the past two years, Lasa Supergenerics has introduced new blockbuster products such as Oxycozanide to its portfolio, aiming to strengthen its market presence in veterinary APIs. The company also experienced leadership changes with resignations of several independent directors and key compliance officers in 2025. Financially, it has focused on improving operational efficiencies and cash flow management following prior restructuring. Lasa’s acquisition history includes the consolidation of Harishree Aromatics and Chemicals Private Limited, enhancing its market share, diversification, and operational scale. The company actively pursues strategic growth through product launches, capacity expansions, and enhancement of its global export footprint. Lasa Supergenerics is part of the broader Lasa group, which emphasizes comprehensive value chain coverage from discovery research to delivery of healthcare products, especially in veterinary and human health sectors. The company is recognized for its high-quality manufacturing standards, including WHO GMP certification, supporting its leadership position in India’s pharmaceutical API industry with significant export operations. Overall, Lasa Supergenerics Limited is a key player in manufacturing and marketing veterinary and human healthcare APIs and related products, continuously focusing on product innovation, capacity enhancement, and market expansion initiatives to consolidate its presence in both domestic and international markets. These developments reflect its strategic commitment to growth and operational excellence within the pharmaceutical raw materials and intermediates industry.